title: Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.
abstract: OBJECTIVE
  In this prospective multicenter real-life observational cohort study, we investigated the acceptance, adherence and safety of regorafenib, in the treatment of metastatic colorectal cancer patients.
  
  
  METHODS
  A total of 136 patients were recruited at six oncological hospital sites in southern Italy. The adherence to the treatment was measured with patient-completed medication diaries, physician interviews and pill counts.
  
  
  RESULTS
  We found a statistically significant improvement of therapy adhesion by the acceptance questionnaire. The Eastern Cooperative Oncology Group performance status, the level of acceptance, the educational level and the concomitant usage of oral medications influenced the adherence to the treatment.
  
  
  CONCLUSIONS
  Patients' level of education, concomitant other oral medications and patients' general clinical condition may influence the adherence to regorafenib.
authors: U.O. Oncologia, ASL NA2 NORD, Frattamaggiore, Italy.
authors: Salvatore
authors: S
authors: Del Prete
authors: U.O. Oncologia, ASL NA2 NORD, Frattamaggiore, Italy.
authors: Gregorio
authors: G
authors: Cennamo
authors: U.O. Oncologia, Azienda Ospedaliera Specialistica dei Colli, Napoli, Italy.
authors: Luigi
authors: L
authors: Leo
authors: U.O. Oncologia, ASL NA2 NORD, Frattamaggiore, Italy.
authors: Liliana
authors: L
authors: Montella
authors: U.O. Oncologia, Università Campus Biomedico, Roma, Italy.
authors: Bruno
authors: B
authors: Vincenzi
authors: U.O. Oncologia, AORN, 'A Cardarelli', Napoli, Italy.
authors: Maria
authors: M
authors: Biglietto
authors: U.O. Oncologia, Azienda Ospedaliera Specialistica dei Colli, Napoli, Italy.
authors: Francesca
authors: F
authors: Andreozzi
authors: U.O. Oncologia, ASL NA2 NORD, Frattamaggiore, Italy.
authors: Antonella
authors: A
authors: Prudente
authors: U.O. Oncologia, ASL NA2 NORD, Frattamaggiore, Italy.
authors: Patrizia
authors: P
authors: Iodice
authors: U.O. Oncologia, AORN, 'Ruggi D'Aragona', Salerno, Italy.
authors: Clementina
authors: C
authors: Savastano
authors: U.O. Oncologia, ASL NA2 NORD, Frattamaggiore, Italy.
authors: Anna
authors: A
authors: Nappi
authors: U.O. Oncologia, Azienda Ospedaliera Specialistica dei Colli, Napoli, Italy.
authors: Vincenzo
authors: V
authors: Montesarchio
authors: U.O. Oncologia, ASL NA2 NORD, Frattamaggiore, Italy.
authors: Raffaele
authors: R
authors: Addeo
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib
keywords: adherence; clinical practice; compliance; metastatic colorectal cancer; oral therapy; regorafenib; safety